Article
Oncology
David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar
Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Byoung Chul Cho, Dong-Wan Kim, Alexander I. Spira, Jorge E. Gomez, Eric B. Haura, Sang-We Kim, Rachel E. Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom, Jong-Seok Lee, Ji-Youn Han, Misako Nagasaka, Joshua K. Sabari, Sai-Hong Ignatius Ou, Patricia Lorenzini, Joshua M. Bauml, Joshua C. Curtin, Amy Roshak, Grace Gao, John Xie, Meena Thayu, Roland E. Knoblauch, Keunchil Park
Summary: This study evaluated the potential of combining amivantamab and lazertinib in patients with EGFR-mutated NSCLC. The results showed that this combination therapy had improved anti-tumor activity in some patients, with a safety profile similar to monotherapy.
Article
Oncology
Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue'e Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Qingyu Wang
Summary: HLX02, an approved biosimilar of trastuzumab, showed equivalent efficacy, safety, and immunogenicity compared with reference trastuzumab in patients with HER2-positive recurrent or metastatic breast cancer. The study concluded that HLX02 is a reliable alternative to trastuzumab for these patients.
Article
Biochemistry & Molecular Biology
Qi Shao, Shuangjie Li, Qi Cao, Haotian Gu, Jiajia Zhang, Youwen Zhang, Kaili Zhang, Wanglong Zheng, Nanhua Chen, Shaobin Shang, Jianzhong Zhu
Summary: Monoclonal antibodies (mAbs) against porcine RLR proteins were developed, targeting different regions for RIG-I, MDA5, and LGP2. It was found that the RIG-I and MDA5 mAbs were specific to pigs, while the LGP2 mAbs showed reactivity with both pigs and humans. This study not only provides useful tools for porcine RLR antiviral signaling research, but also reveals insights into porcine innate immunity and immune biology by highlighting the porcine species specificity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Zhi-juan Liang, Jie Tan, Lei Tang, Zuo-bin Xie, Gan-jun Chen, Guo-jian Liu, Lin Yuan, Kai-xin Wang, Hua-ping Ding, Hong Qiu, Qi Wang, Gui-feng Wang, Yi-li Chen, Chun-he Wang
Summary: NGF inhibitor DS002 effectively alleviates pain in animal models of chemotherapy-induced peripheral neuropathy (CIPN), showing potential for the treatment of CIPN pain in the clinic.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Biochemistry & Molecular Biology
Kwang-Hyeok Kim, Jin-Ock Kim, Jeong-Yang Park, Min-Duk Seo, Sang Gyu Park
Summary: Lung cancer is a major cause of cancer-related deaths, with small cell lung cancer (SCLC) accounting for a significant portion. Overexpression of c-Kit is a characteristic of SCLC. This study found that the antibody-drug conjugate 4C9-DM1 shows potential as a therapeutic agent for SCLC, as it efficiently induces apoptosis and inhibits tumor growth. Combination treatment with other drugs further enhances its anti-tumor effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Toshihiko Doi, Yasutoshi Kuboki, Yoichi Naito, Masahiro Ishida, Tetsuya Tanaka, Yoshito Takeuchi
Summary: This study assessed the use of Xentuzumab in Japanese patients with solid tumors and found that it was well tolerated and showed evidence of anti-tumor activity at the appropriate biological dose.
Article
Oncology
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, Jose Baselga
Summary: This study evaluated the efficacy and tolerability of gefitinib in patients with advanced non-small-cell lung cancer. The results showed similar efficacy and tolerability between the 250mg and 500mg doses of gefitinib, with no significant differences in symptom improvement rates and survival times. Adverse events, mainly skin reactions and diarrhea, were generally mild, and lower in the 250mg dose group.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Charles L. Vogel, Melody A. Cobleigh, Debu Tripathy, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael Press
Summary: The purpose of this study was to evaluate the efficacy and safety of single-agent trastuzumab as first-line treatment in women with HER2-positive metastatic breast cancer. The results showed that single-agent trastuzumab had good efficacy and tolerability in the treatment of HER2-positive metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Immunology
Basudev Paudyal, Adam McNee, Pramila Rijal, B. Veronica Carr, Alejandro Nunez, John McCauley, Rodney S. Daniels, Alain R. Townsend, John A. Hammond, Elma Tchilian
Summary: Prophylactic intravenous administration of specific monoclonal antibodies in pigs showed significant reduction in lung pathology and virus loads, but not consistent reduction in nasal shedding. The effect on lung pathology and virus load is consistent across different doses, suggesting that lower doses may be effective in reducing disease severity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Analytical
He Chen, Yuan Ding, Jiao Li, Lianrun Huang, Gualberto Gonzalez-Sapienza, Bruce D. Hammock, Minghua Wang, Xiude Hua
Summary: This study presents a new unconstrained ratiometric signal approach by integrating negative-readout competitive and positive-readout noncompetitive immunoassays into a single assay. The method has been demonstrated to be applicable to fluorescence and colorimetry readouts, and exhibits strong anti-interference ability to external light environment.
ANALYTICAL CHEMISTRY
(2022)
Article
Chemistry, Analytical
Fatemeh Maleki, Mohammad-Reza Rashidi, Habib Razmi, Marjan Ghorbani
Summary: A novel electrochemical immunosensor based on immobilization of monoclonal antibody on PAN/Zein-rGO nanofibers was developed for ultrasensitive determination of IGF-1. The PAN/Zein nanofibers provided flexibility and high specific surface area, while rGO nanoparticles improved detection sensitivity and anti-IGF-1 immobilizing. The proposed method showed good selectivity, stability, reproducibility, and acceptable results in the analysis of IGF-1 in human plasma samples.
Article
Oncology
Min Wu, Xiaojiao Li, Deming Yang, Meng Wang, Hong Zhang, Cuiyun Li, Jiajia Mai, Lizhi Yang, Yunpeng Qi, Jin-Chen Yu, Xiaolei Yang, Zhaohe Wang, Cailing Gu, Yanhua Ding
Summary: This study aimed to evaluate the similarity of BAT2206 to its originator, ustekinumab, in Chinese male subjects. The results showed that BAT2206 and ustekinumab demonstrated similar pharmacokinetic profiles, immunogenicity, and safety in the participants.
Article
Oncology
Srivandana Akshintala, R. Taylor Sundby, Donna Bernstein, John W. Glod, Rosandra N. Kaplan, Marielle E. Yohe, Andrea M. Gross, Joanne Derdak, Haiyan Lei, Alexander Pan, Eva Dombi, Isabel Palacio-Yance, Kailey R. Herrera, Markku M. Miettinen, Helen X. Chen, Seth M. Steinberg, Lee J. Helman, Leo Mascarenhas, Brigitte C. Widemann, Fariba Navid, Jack F. Shern, Christine M. Heske
Summary: The purpose of this study was to evaluate the safety and efficacy of the combination of ganitumab, an anti-IGF-1R antibody, and dasatinib, a multi-kinase inhibitor targeting YES, in patients with RMS. The results showed that this combination therapy had a low overall response rate, with only a partial response in some patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Layla Damen, Melitza S. M. Elizabeth, Stephany H. Donze, Sjoerd A. A. van den Berg, Laura C. G. de Graaff, Anita C. S. Hokken-Koelega
Summary: In children with Prader-Willi syndrome receiving GH treatment, high immunoreactive IGF-I levels are often observed, while free IGF-I levels are low, indicating a significant discrepancy between the two.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
J. Connor Wells, Aven Sidhu, Keyue Ding, Martin Smoragiewicz, Daniel Y. C. Heng, Frances A. Shepherd, Peter M. Ellis, Penelope A. Bradbury, Derek J. Jonker, Lillian L. Siu, Karen A. Gelmon, Christos Karapetis, Jeremy Shapiro, Louise Nott, Christopher J. O'Callaghan, Wendy R. Parulekar, Lesley Seymour, Jose G. Monzon
Summary: One in 5 patients in phase III clinical trials report using complementary medicines (CM), with the highest proportion seen in breast cancer patients (35.6%). CM users have more favorable baseline prognostic factors and lower rates of adverse events. After adjusting for baseline differences, CM use is associated with longer overall survival in patients with lung cancer.
Article
Oncology
Natasha B. Leighl, Scott A. Laurie, Glenwood D. Goss, Brett G. M. Hughes, Martin Stockler, Ming-Sound Tsao, David M. Hwang, Phillipe Joubert, Swati Kulkarni, Normand Blais, Anil A. Joy, Mihaela Mates, Punam Rana, Sunil K. Yadav, Craig Underhill, Christopher Lee, Penelope A. Bradbury, Andrea Hiltz, Janet Dancey, Keyue Ding, Francisco Vera-Badillo
Summary: This study compared the efficacy of combination chemoimmunotherapy and dual checkpoint inhibition as first-line treatment for metastatic NSCLC. The results showed similar overall survival between the two treatment approaches, but combination chemoimmunotherapy demonstrated better progression-free survival and overall response rate. However, the incidence of adverse events was higher in the combination chemoimmunotherapy group.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
John Hilton, Karen Gelmon, Philippe L. Bedard, Dongsheng Tu, Hong Xu, Anna V. Tinker, Rachel Goodwin, Scott A. Laurie, Derek Jonker, Aaron R. Hansen, Zachary W. Veitch, Daniel J. Renouf, Linda Hagerman, Hongbo Lui, Bingshu Chen, Deb Kellar, Irene Li, Sung-Eun Lee, Takako Kono, Brian Y. C. Cheng, Damian Yap, Daniel Lai, Sean Beatty, John Soong, Kathleen I. Pritchard, Isabel Soria-Bretones, Eric Chen, Harriet Feilotter, Moira Rushton, Lesley Seymour, Samuel Aparicio, David W. Cescon
Summary: CX-5461, a G-quadruplex stabilizer, exhibits synthetic lethality in homologous recombination-deficient models. This multicentre phase I trial in patients with solid tumors demonstrates the clinical proof-of-concept for CX-5461, with a recommended phase II dose of 475 mg/m(2) in patients with defective homologous recombination. Responses are observed in 14% of patients, primarily in those with defective homologous recombination.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Conrad B. Falkson, Emily T. Vella, Peter M. Ellis, Donna E. Maziak, Yee C. Ung, Edward Yu
Summary: This guideline provides recommendations for the most effective therapy for patients with thymic epithelial tumors, including thymoma, thymic carcinoma, and thymic NETs. The recommendations cover surgical, radiation, and systemic treatments, based on the stage of disease using the TNM staging system.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
E. K. Donovan, G. R. Pond, H. Seow, P. M. Ellis, A. Swaminath
Summary: This study aimed to evaluate the risk of cardiac toxicity in advanced lung cancer patients after radical radiotherapy. Patients with stage III non-small cell lung cancer (NSCLC) receiving chemoradiotherapy were included from a population-based cohort in Ontario, Canada. The primary outcome was cardiac toxicity, assessed as cardiac events or congestive heart failure, at 1 and 5 years post-chemoradiotherapy. Secondary outcomes included overall survival, survival in relation to post-treatment cardiac events, and the impact of radiotherapy technique on cardiac toxicity. The results showed that the cumulative incidence of cardiac toxicity at 5 years was 20.3% (18.4-22.3) in the NSCLC patients. Median survival was shorter in NSCLC patients who experienced a cardiac event post-chemoradiotherapy compared to those who did not. There was a trend towards increased cumulative cardiac toxicity with three-dimensional conformal radiotherapy compared to other techniques. In conclusion, there is a high risk of cardiac events and congestive heart failure 5 years after radical thoracic radiotherapy, and survival is inferior in patients who experience a cardiac event post-treatment. More conformal radiotherapy techniques may help reduce cardiac toxicity. Further studies should explore adaptive treatment planning and close monitoring and intervention in this high-risk group after chemoradiotherapy.
Article
Oncology
Ranjan Sur, Gregory Pond, Conrad Falkson, Ming Pan, James Wright, Andrea Bezjak, Anne Dagnault, Edward Yu, Maha Almahmudi, Serge Puksa, Darin Gopaul, Theos Tsakiridis, Anand Swaminath, Peter Ellis, Timothy Whelan
Summary: The purpose of this study was to evaluate the potential clinical benefit of adding high-dose-rate intraluminal brachytherapy (HDRIB) to external beam radiation therapy (EBRT) for patients with advanced non-small cell lung cancer (NSCLC). The results showed small to moderate improvements in symptom relief with combined therapy, but they did not reach statistical significance. Further research is needed before recommending HDRIB in addition to EBRT for palliation of lung cancer symptoms.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Review
Oncology
Conrad B. Falkson, Emily T. Vella, Peter M. Ellis, Donna E. Maziak, Yee C. Ung, Edward Yu
Summary: This systematic review evaluated treatment options for patients with thymic epithelial tumors and found that postoperative radiotherapy provides overall survival benefits for patients with thymic carcinoma and thymoma, especially those at high risk. Chemotherapy also showed efficacy for thymic carcinoma and thymoma, but results for neoadjuvant chemotherapy and minimally invasive surgical techniques may be affected by selection bias. Further large-scale prospective studies are needed to control confounders.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Shijie Zhou, Filipe Cirne, Justin Chow, Arman Zereshkian, Louise Bordeleau, Sukhbinder Dhesy-Thind, Peter M. Ellis, Som D. Mukherjee, Nazanin Aghel, Darryl P. Leong
Summary: This study investigated the intermediate-term clinical outcomes of patients who underwent permissive cardiotoxicity. The results showed that 92% of patients completed the trastuzumab treatment, while 6% experienced severe left ventricular dysfunction or clinical heart failure and prematurely discontinued therapy. At the final follow-up, 14% of patients still had mild cardiotoxicity. Although most patients recovered their left ventricular function after trastuzumab discontinuation or completion, persistent cardiotoxicity was observed in some patients.
Letter
Cardiac & Cardiovascular Systems
Peter A. Kavsak, Brock Hoard, Katharine Mackett, Som D. Mukherjee, Louise Bordeleau, Peter M. Ellis, Sukhbinder Dhesy-Thind
Article
Oncology
Olga-Demetra Biziotis, Evangelia Evelyn Tsakiridis, Amr Ali, Elham Ahmadi, Jianhan Wu, Simon Wang, Bassem Mekhaeil, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Bassam Abdulkarim, Ranjan K. Sur, Aruz Mesci, Peter Ellis, Tobias Berg, Jonathan L. Bramson, Paola Muti, Gregory R. Steinberg, Theodoros Tsakiridis
Summary: The diabetes drug canagliflozin inhibits NSCLC cell proliferation and the mTOR pathway. It can enhance response rates when combined with cytotoxic therapy, making it a promising therapy for NSCLC.
MOLECULAR ONCOLOGY
(2023)
Review
Oncology
Darryl P. Leong, Filipe Cirne, Nazanin Aghel, Rocio C. Baro Vila, Germano D. Cavalli, Peter M. Ellis, Jeff S. Healey, Richard Whitlock, Dina Khalaf, Hira Mian, Sanjit S. Jolly, Shamir R. Mehta, Susan Dent
Summary: This study reviews the use of invasive cardiac interventions in patients with active advanced cancer, discussing the benefits of surgery, perioperative considerations, and patient survival expectations. Limited evidence currently exists to guide interventions in these patients, highlighting the need for a rational framework for clinical recommendations.
JACC: CARDIOONCOLOGY
(2023)
Article
Oncology
Barbara L. Melosky, Natasha B. Leighl, David Dawe, Normand Blais, Paul F. Wheatley-Price, Quincy S. -C. Chu, Rosalyn A. Juergens, Peter M. Ellis, Alexander Sun, Devin Schellenberg, Diana N. Ionescu, Parneet K. Cheema
Summary: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with limited treatment options and poor outcomes. Recent developments in first-line and subsequent therapeutic approaches have prompted a consensus review on the treatment of extensive-stage SCLC (ES-SCLC). The resulting consensus recommendations will guide evidence-based management and improve patient outcomes.
Review
Oncology
Arani Sathiyapalan, Ziad Baloush, Peter M. Ellis
Summary: Recent advances in curative intent therapy for stage III NSCLC have shown significant improvements in disease-free survival and overall survival. Adjuvant atezolizumab or pembrolizumab following chemotherapy have been found effective for resectable NSCLC patients. Adjuvant osimertinib therapy has shown significant improvements in both DFS and OS for patients with EGFR gene mutation. Neoadjuvant or perioperative chemotherapy plus immunotherapy have demonstrated significant improvements in pathologic complete response and event-free survival.
Review
Oncology
Arani Sathiyapalan, Michela Febbraro, Gregory R. Pond, Peter M. Ellis
Summary: Combining immune checkpoint inhibitors (ICI) with chemotherapy for untreated small cell lung cancer (SCLC) patients can significantly improve survival, reduce the risk of disease progression, and have minimal increase in toxicity.
Article
Oncology
Doreen A. Ezeife, Eldon Spackman, Rosalyn A. Juergens, Janessa J. Laskin, Jason S. Agulnik, Desiree Hao, Scott A. Laurie, Jennifer H. Law, Lisa W. Le, Lesli A. Kiedrowski, Barbara Melosky, Frances A. Shepherd, Victor Cohen, Paul Wheatley-Price, Rachel Vandermeer, Janice J. Li, Roxanne Fernandes, Aria Shokoohi, Richard B. Lanman, Natasha B. Leighl
Summary: Adding liquid biopsy (LB) to tissue testing (TT) can detect more actionable genomic alterations in patients with advanced non-small cell lung cancer (NSCLC) in the Canadian healthcare system. The LB + TT strategy saves costs and allows more patients to receive appropriate targeted therapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)